Somaxon Settles IP Rows With Mylan, Par Over Insomnia Drug

Law360, New York (July 18, 2012, 6:43 PM EDT) -- Somaxon Pharmaceutical Inc. said Tuesday it had settled patent infringement suits against generic drugmakers Mylan Inc. and Par Pharmaceutical Cos. Inc., striking deals that will keep generic versions of Somaxon’s insomnia treatment drug from hitting the U.S. market until 2020.

By retaining its exclusivity on insomnia treatment drug Silenor for another eight years, San Diego-based Somaxon caps a more than year-long campaign of patent enforcement actions to keep competitors from developing and selling generic versions of Silenor, which currently is its only product and primary revenue...
To view the full article, register now.